We use cookies to customise content for your subscription and for analytics.If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Congressional hearing on 340B program postponed

The U.S. House of Representatives Committee on Energy and Commerce, Subcommittee on Health had planned a hearing on March 5, 2015, to review the functionality of the 340B Drug Pricing Program to understand how it impacts patients, providers, manufacturers, and other stakeholders. The hearing, entitled “Examining the 340B Drug Pricing Program,” was postponed due to inclement weather last week in the D.C. area. Information about the scheduled hearing, including a link to the Subcommittee’s background memo, is available by clicking here.

Compare jurisdictions: M&A

“I make an effort to read at least several articles each day and regularly share the particularly relevant or interesting articles with my colleagues. I greatly appreciate the inclusion of the Lexology service by the State Bar of Texas and have recommended that my friends and colleagues join the Corporate Counsel Section of the State Bar in order to obtain this service for themselves.”